News | December 5, 2019

GE Healthcare Life Sciences Allies With Pharmadule Morimatsu To Expand KUBio

Source: GE Healthcare Life Sciences

Uppsala, Sweden – The KUBio “factory in a box” is expanding to accelerate the accessibility of biotherapeutics on a global scale. Additional modular platforms will be introduced in 2020 allowing biopharma manufacturers to quickly scale up vaccines, viral vector-based therapies, and other novel modalities.

To do so, GE Healthcare Life Sciences will work closely with Pharmadule Morimatsu, a company specializing in the design and manufacture of modular facilities. Pharmadule will provide engineering design, construction, installation, and validation services, based on GE Healthcare Life Sciences’ proprietary design.

Olivier Loeillot, General Manager BioProcess at GE Healthcare Life Science, says: “We are combining our decades-long expertise in biomanufacturing with Pharmadule’s proven excellence in modular construction to support the growth of the biopharmaceutical industry. What biomanufacturers need is fast access to reliable technologies, cost-effective investments, and speed to market. KUBio offers all this, while continuing to extend and adapt to the dynamics of the market.”

Helen Zhang, CEO of Pharmadule, says: “Joining expertise with GE Healthcare Life Sciences is an important milestone. Through this collaboration, we will leverage our capacity to execute effective projects from conceptual design to a qualified modular facility and support the expansion of the KUBio biomanufacturing facility offering. This fits very well with our modular concept, which includes global turn-key delivery, from early design through fabrication and installation up to operational qualification on site.”

Biopharmaceuticals are the fastest-growing class of medicines, used in the treatment of a wide range of diseases, including rheumatoid arthritis, certain cancers, and diabetes. The biopharmaceutical market grows at a compound annual growth rate (CAGR) of 13.8% from 2018 to 2025 and is forecasted to reach $526 billion by 2025(1).

GE Healthcare Life Sciences launched the first off-the-shelf KUBio modular facility in 2012 for the biomanufacturing of monoclonal antibodies. The KUBio portfolio has expanded over the years to support the production of vaccines and viral vectors. GE Healthcare Life Sciences has provided KUBio facilities to JHL, Pfizer, and BeiGene. In collaboration with Pharmadule, GE Healthcare Life Sciences is currently deploying a KUBio facility in Guangzhou, China.

About GE Healthcare Life Sciences

GE Healthcare Life Sciences helps therapy innovators, researchers, and healthcare providers accelerate how precision diagnostics and therapies are invented, made, and used. Our products enable biological analysis, research, development, and the manufacture of advanced therapies and vaccines. Life Sciences is part of the $19.8 billion healthcare business of GE (NYSE: GE). With over 100 years of experience in the healthcare industry and more than 50,000 employees globally, GE Healthcare helps efficiently improve outcomes for patients, healthcare providers, researchers, and life sciences companies around the world. Visit our website https://www.gelifesciences.com/about-us for more information.

About Pharmadule Morimatsu

Pharmadule was founded in 1986 and has from the start provided its expertise in modular construction technology to various industries. Today, Pharmadule Morimatsu AB enjoys a strong global position as an authority in designing, constructing and delivering state-of-the-art modular manufacturing facilities for the pharmaceutical & biopharmaceutical industries. More than 70 projects have been delivered using Pharmadule's modular concept and both multinational and local companies have benefited from our delivery method. To learn more about the company please visit: www.pharmadule.com

Sources:

Market Watch (2019) Biopharmaceuticals Market Projected to Grasp $526,008 Million by 2025 With a CAGR 13.8% – Allied Market Research

Source: GE Healthcare Life Sciences